Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide, which can be explained at least in part by its propensity towards metastasis and the limited efficacy of adjuvant therapy. MetastamiRs are miRNAs that promote or suppress migration and metastasis of cancer cells, and their functional status is significantly correlated with HCC prognosis. Unlike targeted therapy, metastamiRs have the potential to target multiple genes and signaling pathways and dramatically suppress cancer metastasis. In this review, we discuss the regulatory role of metastamiRs in the HCC invasion-metastasis cascade. Moreover, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis has shown that many extensively studied metastamiRs target several critical signaling pathways and these have remarkable therapeutic potential in HCC. The information reviewed here may assist in further anti-HCC miRNA drug screening and development.
INTRODUCTION

P
RIMARY LIVER CANCER is the sixth most common cancer and the third leading cause of cancer mortality worldwide. Hepatocellular carcinoma (HCC) accounts for nearly 80-90% of primary liver cancer, and the majority of HCC patients have underlying chronic liver diseases. 1, 2 Although early surveillance technology has extended the life of patients diagnosed at an early stage, the high rate of recurrence after surgery as well as intrahepatic metastases still hamper long-term survival. [2] [3] [4] Patients with HCC with portal vein invasion or extrahepatic metastases at the time of diagnosis have little chance of long-term survival. 5 Thus, a deeper understanding of the mechanism and regulation of metastasis is necessary for improving HCC prognosis.
Invasion and metastasis are complex multistep processes often referred to as the invasion-metastasis cascade, which involves a succession of cell-biologic changes. Briefly, cancer cells separate from the primary tumor, gain motility, intravasate (enter the bloodstream), survive within the circulating blood flow, and extravasate (exit the bloodstream) to form a new mass. Various genes and signaling pathways are involved in regulating this evolutionary process. 6 Protein coding genes are considered safeguards or checkpoints of cellular processes that preserve cellular homeostasis by switching on or off the expression of certain key regulators, also known as tumor suppressor genes or oncogenes. More recently however, abundant classes of small endogenous non-coding RNAs (miRNAs), 20-25 nucleotides in length, have been reported to regulate these protein coding genes. Generally, miRNAs modulate gene expression by repressing mRNA transcription or promoting mRNA degradation through sequence-specific binding of the 3′-untranslated region (3′-UTR). 7 Since the first report in 2002 of a miRNA involved in the development of cancer, an increasing number of miRNAs have been shown to be involved in various cancers, including HCC. 8, 9 By targeting different genes, miRNAs can regulate various signaling pathways, affecting tumorigenesis, progression, invasion, and metastasis. Accordingly, miRNAs have been classified as oncogenic or tumor suppressor miRNAs. Oncogenic miRNAs are upregulated in cancer cells and target tumor suppressor genes, which facilitates carcinogenesis. 10 Conversely, tumor suppressor miRNAs downregulate the expression of oncogenes to suppress cancer development and progression. 11 The term "metastamiRs" was introduced by Edmonds et al. to describe miRNAs that promote or suppress migration and metastasis of cancer cells. 12 To date, nearly 70 metastamiRs related to HCC have been identified through in vivo and in vitro experiments. They are involved in different steps of the invasion-metastasis cascade and in various signaling pathways (Figs 1, 2) . Dysregulation of these metastamiRs are significantly associated with clinical outcome (Table 1) . Indeed, certain metastamiRs have been developed as anticancer nucleic acid drugs and have entered clinical or preclinical studies. [36] [37] [38] Because metastasis is the most deadly hallmark of HCC, metastamiRs are promising therapeutic candidates.
In this review, we focus on the latest findings regarding the role of metastamiRs in HCC. We first provide an overview of the regulatory role of metastamiRs in the HCC invasion-metastasis cascade. We then summarize the prognostic value of these metastamiRs. Finally, we present bioinformatic analysis of metastamiR target genes and discuss potential future directions for miRNA therapies in HCC. The information compiled here comprehensively describes the role of metastamiRs in HCC, thus potentially aiding future anti-HCC miRNA drug screening and development research.
MicroRNAs involved in initiation of metastasis
The initiation steps of metastasis involve the detachment of tumor cells from the primary tumor, followed by dissociation of these malignant cells into the surrounding stroma. This is facilitated by loss of focal adhesions and adherens junctions, which then also facilitate cell-matrix interactions, which enables cell migration. This process is also known as epithelial-mesenchymal transition (EMT), an early metastatic step that occurs prior to the acquisition of motility and local invasion. Epithelial-mesenchymal transition is regulated by various signaling molecules and pathways including E-cadherin, integrins, transforming growth factor-β (TGF-β), Wnt/β-catenin, nuclear factor-κB (NF-κB), and tyrosine kinase receptor (RTK) signaling.
E-cadherin, a critical cell-cell and cell-extracellular matrix (ECM) adhesion molecule, facilitates epithelial cell adhesion to inhibit cell migration. E-cadherin is often downregulated in metastatic tumors, including HCC. Figure 1 MetastamiRs involved in the cancer invasion-metastasis cascade. CTC, circulating tumor cell; miR, microRNA; MMP, matrix metallopeptidase; NF-κB, nuclear factor-κB; ROCK, Rho-associated protein kinase; RTK, receptor tyrosine kinase; TGF-β, transforming growth factor-β; VEGF, vascular endothelial growth factor. MicroRNA30-3p is significantly downregulated in HCC compared with adjacent normal tissues, and restoring its expression can increase E-cadherin protein levels and suppress invasiveness and metastasis capability of Bel-7402 HCC cells in vitro. 39 In hepatoma cells, miR-148a was shown (by gain-and loss-of-function studies) to promote the expression of E-cadherin and to reduce the levels of N-cadherin and vimentin. 40 Integrins form cell-cell and cell-ECM bridges. By directly targeting integrin β1, miR-134 attenuates cell-cell and cell-ECM junctions and induces HCC metastasis. 41 Zhang et al. also showed that miR-26a promotes anoikis in human HCC cells by targeting integrin α-5.
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Transforming growth factor-β signaling is one of the major inducers of EMT. Transforming growth factor-β binds to its receptors, leading to phosphorylation of SMAD2 and SMAD3, which in turn form trimers with SMAD4 that translocate to the nucleus to regulate the expression of its target genes along with other accessory factors, like Snail, zinc finger E-box binding homeobox 1 (ZEB), and Twist. This process is modulated by several miRNAs. MicroRNA-590-5p is upregulated in HCC cell lines, such as HepG2, Hep3B, and MHCC97L (HCC cells with migratory capacity), compared to the normal hepatocellular cell line L02. Luciferase reporter assay has revealed the direct regulation of TGF-β RII by miR-590-5p. Downregulation of miR- Figure 2 Landscape of targeted Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of metastamiRs in hepatocellular carcinoma (HCC). All target genes used for KEGG enrichment analysis identified by luciferase reporter assay and detailed information were obtained from the latest version of the miRTarBase database. 13 KEGG enrichment analysis was carried out in DAVID. 14 590-5p in HepG2 cells leads to proliferation arrest and reduced invasion capability. In contrast, overexpression of miR-590-5p could promote proliferation and invasion in L02 cells. 43 MicroRNA-125b also participates in EMT through TGF-β signaling by directly modulating SMAD2 and SMAD4 in HCC. 21 Moreover, through gain-and lossof-function studies, Kan et al. showed that miR-520 g promotes HCC cell migration, invasion, and EMT by blocking SMAD7 expression. 44 The Wnt/β-catenin signaling pathway plays a central role in hepatocarcinogenesis and HCC metastasis. Approximately 50% of HCC patients have activated Wnt signaling pathways. 45 In MHCC97H cells (HCC cells with migratory capacity), miR-148 inhibits cell metastasis and cancer stem cell-like properties by blocking Wnt pathway activation. 46 In addition, through directly and indirectly targeting catenin (cadherin-associated protein) β1, miR-214 can modulate β-catenin signaling and suppress invasion, stem-like traits, and recurrence of HCC. 23 Furthermore, through gain-and loss-of-function studies, Du et al. observed that overexpression of miR-126-3p can dramatically suppress HCC metastasis and angiogenesis. Dual luciferase reporter assay demonstrated that LRP6, a well-known activator of β-catenin, is one of the direct targets of miR-126-3p. 47 Nuclear factor-κB signaling is one of the central links between inflammation and tumor genesis. Both IκB kinase α and TGF-β activated kinase 1/MAP3K7 binding protein 3 are critical modulators of NF-κB signaling. Through a high-throughput luciferase reporter screen assay, Ding et al. verified that nearly 20 miRNAs can directly target NF-κB signaling in HCC. 48 Further in vitro and in vivo experimental studies showed that miR-195, a significantly downregulated miRNA in HCC, exerts its tumor suppressive function by directly targeting the 3′-UTR of IκB kinase α and TGF-β activated kinase 1/MAP3K7 binding protein 3. 48 Approximately 50% of patients with early stage HCC and almost all those with advanced stage HCC have activated mitogen-activated protein kinase signal pathways. 49, 50 Fibroblast growth factor (FGF), epidermal growth factor (EGF), and MET typically bind and activate mitogenactivated protein kinase signaling. Fibroblast growth factor family members are frequently overexpressed in human malignancy and play a critical regulatory role in tumor growth, invasion, and metastasis. Aberrant expression of miR-140-5p and miR-188-5p, both regulators of FGF, has 52 Metastasis suppressor 1 (MTSS1) can prolong EGF signaling by enhancing the localization of the EGF receptor to the plasma membrane. However, at high cell densities, MTSS1 negatively impacts EGF signaling and inhibits metastasis. 53 Both miR-182 and miR-135 can downregulate MTSS1 and inhibit metastasis of HCC. 26, 30 Dysregulation of the oncogene c-MET (also known as MET or hepatocyte growth factor receptor) can trigger tumor proliferation, angiogenesis, and metastasis. Overexpression of miR-34a downregulates c-MET and inhibits HCC proliferation and metastasis. 54 In HepG2 cells, ectopic expression of miR-34a potently suppresses cell migration and invasion in a c-MET-dependent manner and reduces c-Met-induced phosphorylation of extracellular signal-regulated kinases 1 and 2. 55 In addition, by directly targeting c-MET, activating phosphorylation of protein kinase B (AKT)-Ser473, and inhibiting phosphorylation of glycogen synthase kinase-3β-Ser9, miR-148a attenuates Met/Snail signaling, thereby inhibiting hepatoma cells metastasis. 40 Moreover, miR-198 and miR181a-5p have been shown to inhibit HCC metastasis by directly targeting c-MET. 56, 57 Another study also reported that ectopic overexpression of miR-124 could inhibit EMT and efficiently suppress HCC metastasis. 32 The phosphatidylinositol 3-kinase (PI3K)-AKT axis is one of important signaling pathways downstream of RTK signaling, which is known to participate in cell proliferation, survival, and motility/metastasis. Several miRNAs have been implicated in the regulation of HCC metastasis by targeting this signaling axis. For example, miR-486-5p, miR-126-3p, and miR-7 have been shown to be effective regulators of different PI3K subunits. Silencing these miRNAs can dramatically reduce tumor growth and extrahepatic migration. 19, 47, 58 Phosphatase and tensin homolog (PTEN) is a negative modulator of the PI3K-AKT pathway, and is the target of miR-494 and miR-21.
58,59
By dephosphorylating phosphatidylinositol 3,4, 5-trisphosphate and focal adhesion kinase, PTEN inhibits AKT signaling and negatively regulates cell-ECM interactions. Overexpression of miR-21 and miR-494 suppresses tumor suppressor PTEN, thereby contributing to HCC invasion and metastasis. 58, 59 Transcription factors like ZEB1/2, Snail, and the forkhead box (FOX) family are the nuclear effectors of the RTK signal pathway. By directly targeting ZEB1, the miR-200 family, miR-429, and miR-205 block HCC metastasis both in vitro and in vivo. 24 FoxQ1 is a master regulator of HCC metastasis. By using RNAi manipulation, Zhang et al. showed that FoxQ1 is a direct target of miR-442a. Through a double-negative feedback loop between miR442a and FOXG1/Q1/E1, miR-442 exerts its regulatory role in HCC growth and metastasis. 62 E2F3, a member of the E2F family of transcription factors, plays a crucial role in controlling the cell cycle as well as tumor suppressor proteins. E2F3 and miR-141/-144/-217 expression is negatively correlated in in vitro studies; and ectopic overexpression of miR-141/-144/-217 remarkably reduces cell proliferation, and suppresses migration and invasion of HCC cells.
63-65
Role of miRNAs in local invasion
The basement membrane provides a critical barrier to invasion. Matrix metallopeptidases (MMPs) can degrade components of the basement membrane, thereby weakening its barrier function. Dysregulation of MMPs, such as MMP-2 and MMP-9, has been observed in many types of cancer, including HCC. 66, 67 Several dysregulated miRNAs that directly target MMPs have been identified as promising candidates for anti-HCC therapy. MicroRNA-29b is aberrantly expressed in various cancers, 68 and is significantly downregulated in HCC compared with paired normal liver. Xiong et al. found that decreased expression of miR29b is significantly associated with poor prognosis in HCC patients. Further investigation in in vitro and in vivo experiments indicated that Mcl-1, Bcl-2, and MMP-2 are direct targets of miR-29b; by directly targeting the 3′-UTR of these genes, miR-29b dramatically suppresses microvessel invasion and intrahepatic metastasis. 69, 70 Both miR-133a and miR-338-3p are downregulated in HCC and strongly inhibit HCC invasion by suppressing MMP-9. 20, 71 Other miRNAs like miR-125 and miR-127 also exert their metastasis suppressor role by directly target MMP-11 and MMP-13.
31,72 Downregulation of these miRNAs therefore result in activation of MMPs and facilitate tumor cell metastasis.
Role of miRNAs in tumor cell motility
Following disruption of cellular adhesion, tumor cells acquire motility by forming cellular protrusions, termed lamellipodia and filopodia, which are found on the leading edge of motile cells. Loss of cellular adhesion and the acquisition of motility are the result of reshaping of the cytoskeleton, which is primarily governed by Rho family proteins, such as RhoA, Rac, and cell division cycle 42 (CDC42). 73 Rho and Rho-associated protein kinase (ROCK) signaling governs cell movement by regulating actomyosin contraction and formation of stress fibers. This pathway is frequently altered in HCC and is involved in HCC metastasis. RhoA and ROCK2 are at the center of this pathway and are also regulated by several miRNAs. 76 RhoC is another member of the Rho family that fulfills similar functions to RhoA. Apart from these metastasis-suppressing miRNAs, Yau et al.
showed that miR-106b promotes HCC metastasis by upregulating the Rho GTPases, RhoA and RhoC. 77 Both Rac and CDC42 both regulate lamellipodia formation. Rac1, the most important member of the Rac subfamily, is significantly overexpressed in metastatic HCC tissues and aggressive HCC cell lines. 78, 79 Several miRNAs have been identified as Rac1 regulators in HCC: miR-142-3p, which is downregulated in HCC, can suppress Rac1 expression and the motility and the invasive ability of HCC cell lines in vitro;
80 miR-100 also suppresses Rac1 signaling and HCC metastasis, which also targets isoprenylcysteine carboxylmethyltransferase (ICMT), an essential postprenylation processing enzyme, to inhibit ICMTmediated methylation of Rac1. 34 Moreover, downregulated miR-195 leads to increasing expression of VAV2 and CDC42, which in turn activate VAV2/Rac1/CDC42 signaling as well as formation of lamellipodia and promote HCC metastasis. 81 
Role of miRNAs in angiogenesis and vascular invasion
Angiogenesis-derived tumor neovasculature meets the tumor's requirements of nutrients and oxygen transport as well as excretion of metabolic wastes and carbon dioxide. Vascular endothelial growth factor (VEGF) signaling is the key modulator of angiogenesis. However, VEGF can also disrupt vascular barrier function and induce vascular leakage in diseased tissues. In cancer, VEGF-mediated disruption of the vascular barrier may promote tumor cell extravasation, leading to widespread metastasis. 82 Thus, VEGF is a critical modulator of cancer colonization and metastasis. By indirectly suppressing VEGF, miR-146a and miR-26a dramatically suppress HCC cell invasion and metastasis both in vitro and in vivo. 21 83 Another antiangiogenic miRNA, miR-195, directly suppresses VEGF expression in HCC; 81 and miR-125a inhibits HCC proliferation and metastasis by directly targeting VEGF-A, an important member of the VEGF family.
31 STMN1, also known as Homo sapiens stathmin 1, is a key microtubuleregulatory protein that is positively associated with advanced clinical stage, HCC vascular invasion, and intrahepatic metastasis. 84, 85 Systemic delivery of lentivirus-mediated miR-101 abrogates HCC intrahepatic and distant metastasis in mice by directly targeting STMN1 as well as its negative regulator, enhancer of zeste homolog 2. 33 Collectively, these miRNAs have essential regulatory roles in angiogenesis and vascular invasion that affect HCC metastasis.
MicroRNA therapeutics in HCC: Challenges and future prospects
The genetic background of HCC is very complex. Various signaling pathways that regulate cell proliferation, angiogenesis, invasion, and metastasis are dysregulated in HCC, some of which have been extensively reviewed before [86] [87] [88] [89] (Table 2 ). Many of these are main sources of therapeutic targets for HCC. However, most anti-HCC drugs only target a few targets or signaling pathways Gene count, the number of genes included in the KEGG pathway; hsa, accession number of the KEGG database (details can be found at http:// www.kegg.jp/). KEGG pathway, Kyoto Encyclopedia of Genes and Genomes signal pathway.
( Fig. 3) and their anti-HCC efficacy is very limited, as revealed by previous multicenter randomized controlled clinical trials. Even sorafenib, a multikinase inhibitor that was previously the most effective targeted therapy available to HCC patients, was ineffective in prolonging disease-free survival and overall survival of HCC patients. 92 Fortunately, with technological advances in pharmaceutical preparation, miRNA therapies are now coming into the spotlight. 37, 38, 93 Unlike targeted therapies, the main advantages of miRNA therapeutics is that miRNAs have multiple intracellular targets that may be involved in one or multiple signaling pathways involved in cancer development, progression, and metastasis (Fig. 2, Table 3 ). In other words, miRNAs, especially those that target multiple critical signal pathways in HCC such as miR-34a, are therefore promising therapeutic candidates (Fig. 2) .
Depending on the function of miRNAs, they may be developed as antagonists or mimics, where miRNA antagonists inhibit oncogenic miRNAs, and miRNA mimics (also known as miRNA replacement therapy) restore the function of tumor suppressor miRNAs. 94 However, the biggest challenge in miRNA therapeutics is devising a strategy for safe and effective delivery of miRNA drugs into HCC cells. To overcome this problem, local and systemic delivery strategies have been established that greatly Figure 3 Developing targeted hepatocellular carcinoma therapeutics. Green node, drug; red node, target. 
facilitate miRNA delivery. Moreover, the new generation of "smart" delivery systems that are able to adapt to different microenvironments, conditions, or time series may further facilitate effective miRNA delivery. 93 More interestingly, Drakaki et al. has shown that liver is the primary site of miRNA uptake. 95 Therefore, miRNA-based therapies may be particularly appropriate for liver disease patients. For example, SPC3649, which passed phase I clinical trials, is currently in a phase II trial for treatment of chronic hepatitis C to determine its anti-HCC efficacy. MRX34 is the first miRNA mimic to reach phase I clinical trials (ClinicalTrials.gov identifier: NCT01829971) due to its remarkable anticancer efficacy. Other metastamiRs are currently under preclinical anti-HCC drug development, including miR-26a. 96, 97 When taking into consideration the heterogeneous genetic background of HCC, different miRNAs may have distinct anticancer efficacies. For example, miR-101, miR-107, miR-122, miR-29, miR-365, miR-375, and miR-378 are downregulated in c-Myc and/or AKT/Ras liver tumors, however, the anti-HCC activity of these microRNAs are extremely heterogeneous in c-Myc and AKT/Ras mice. 98 Thus, it is necessary to evaluate anticancer efficacy in appropriate models. As depicted in Figure 2 , like miR34a, several extensively studied tumor suppressor miRNAs (miR-124, miR-29b, miR-200 cluster, miR-125b, miR199a, miR-181a, miR-7, and miR-126) also target more than 60% of critical signaling pathways and may prove to be promising anti-HCC drug candidates. Notably, several miRNAs could be used in combination with each other to acquire more effective results. As an example, in combination, miRNAs from the miR-200 cluster (miR200a/b/c) can in theory target nearly 90% of critical signaling pathways; their true anti-HCC efficacy, however, would certainly require further evaluation.
Another notable problem is the underlying chronic liver diseases of HCC patients, such as viral hepatitis. The virological effects of hepatitis B virus (HBV) and hepatitis C virus (HCV) on hepatocarcinogenesis are quite different. The miRNA expression profile of chronic HBV patients 
also differs from that of chronic HCV patients. [99] [100] [101] For example, miR-122, a famous liver-specific miRNA, could inhibit HBV gene expression by p53-mediated inhibition of HBV transcription through downregulating cyclin G1. 102 However, contrary to its inhibitory role in the HBV life cycle, miR-122 is essential for translation of HCV RNA. [103] [104] [105] Moreover, through integrative analysis, microRNA expression profile of chronic hepatitis B, chronic hepatitis C, and associated HCC from microarray and high-throughput sequencing, Selitsky et al. 99 found only 21.7% (18/83) of differentially expressed miRNAs were shared between chronic hepatitis B and C, and 41.0% (66/161) of differentially expressed miRNAs were shared between chronic hepatitis B-associated HCC and chronic hepatitis C-associated HCC. Thus, further miRNA-based therapies should take the underlying liver disease into consideration.
CONCLUSION
M
ETASTASIS IS THE most deadly hallmark of HCC. MetastamiRs affect multiple genes and signaling cascades, play a critical regulatory role in HCC metastasis, and significantly correlate with HCC prognosis. With recent improvement in specificity and efficacy of RNA delivery systems, new miRNA therapeutic anti-HCC drugs will likely enter clinical trials soon. However, given the widespread genetic heterogeneity of HCC and underlying liver disease, the anticancer efficacy of miRNAs in HCC xenograft models with varying genetic backgrounds will need to be evaluated in future. 
